Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -254.71% is 99% above its 2-year average of -22608.97%, near the high end of its 2-year range (-208681.10%–30.36%).
87.33% above its 12-month average of -2010.60%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -2889.98%.
EBITDA MARGIN
-254.71%
EBITDA MARGIN AVG TTM
-2010.60%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+87.33%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Coya Therapeutics, Inc.
Market Cap
$112.13M
EBITDA Margin
-254.71%
TTM Avg
-2010.60%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$113.17M
EBITDA Margin
-1036.29%
TTM Avg
-1034.54%
3Y Avg
-4587.22%
5Y Avg
-4766.38%
Market Cap
$115.52M
EBITDA Margin
-121.55%
TTM Avg
-120.84%
3Y Avg
-101.07%
5Y Avg
-82.00%
Market Cap
$109.91M
EBITDA Margin
-10.96%
TTM Avg
-24.45%
3Y Avg
-32.87%
5Y Avg
-38.11%
Market Cap
$109.64M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.53M
EBITDA Margin
-408000.00%
TTM Avg
-396456.25%
3Y Avg
-201636.71%
5Y Avg
-201636.71%
Market Cap
$117.42M
EBITDA Margin
-475.96%
TTM Avg
-475.96%
3Y Avg
-272.89%
5Y Avg
-272.89%
Market Cap
$112.03M
EBITDA Margin
-29.32%
TTM Avg
-13.32%
3Y Avg
-6.17%
5Y Avg
-1.07%
Market Cap
$116.54M
EBITDA Margin
-1187.82%
TTM Avg
-1407.84%
3Y Avg
-970.99%
5Y Avg
-809.42%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $112.13M | -254.71% | -2010.60% | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $113.17M | -1036.29% | -1034.54% | -4587.22% | -4766.38% |
| MaxCyte, Inc. (MXCT)vs › | $115.52M | -121.55% | -120.84% | -101.07% | -82.00% |
| Apyx Medical Corporation (APYX)vs › | $109.91M | -10.96% | -24.45% | -32.87% | -38.11% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.64M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $116.53M | -408000.00% | -396456.25% | -201636.71% | -201636.71% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.42M | -475.96% | -475.96% | -272.89% | -272.89% |
| BGM Group Ltd. (BGM)vs › | $112.03M | -29.32% | -13.32% | -6.17% | -1.07% |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | -1187.82% | -1407.84% | -970.99% | -809.42% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $108.33M | -254.86% | -347.69% | -398.28% | -4102.41% |
Gross Margin
99.9%
EBITDA Margin
-254.7%
Operating Margin
-255.1%
Net Margin
-270.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -2889.98% |
| 2026-03-31 | -3041.01% |
| 2025-12-31 | -152.12% |
| 2025-09-30 | -53.59% |
| 2025-06-30 | -3916.29% |
| 2025-03-31 | -2974.24% |
| 2024-12-31 | -208681.10% |
| 2024-06-30 | -94.28% |
| 2024-03-31 | -4317.45% |
| 2023-12-31 | 30.36% |
